Background Novel treatments with superior benefit‐risk profiles are needed to improve the
long‐term prognosis of patients with inflammatory bowel disease ( IBD ). Etrolizumab—a …

… M Williams and EG Stefanich contributed equally to this manuscript. … therapy with corticosteroids
and immunomodulator therapy (eg azathioprine, 6-mercaptopurine and methotrexate) is …

Interleukin (IL)-22 plays protective roles in infections and in inflammatory diseases that have
been linked to its meditation of innate immunity via multiple mechanisms. IL-22 binds …

MTRX1011A is a humanized anti‐CD4 antibody with an amino acid substitution (N434H) to
improve its binding to the neonatal Fc receptor (FcRn). Pharmacokinetic/pharmacodynamic (…

Deamidation of therapeutic antibodies may result in decreased drug activity and undesirable
changes in pharmacokinetics and immunogenicity. Therefore, it is necessary to monitor the …

CD20 is a cell‐surface receptor expressed by healthy and neoplastic B cells and is a well‐established
target for biologics used to treat B‐cell malignancies. Pharmacokinetic (PK) and …

… development stages when there is limited data (eg, design and dose selection in multiple …
Our model with these features (eg, sequential binding and ternary complex formation) was …

Modulating the binding affinities to IgE or changing the FcγR binding properties of anti-IgE
antibodies offers an opportunity to enhance the therapeutic potential of anti-IgE antibodies, …

B cell-activating factor receptor 3 (BR3)-Fc is an IgG1-receptor dimeric fusion protein that
has multiple O-linked glycosylation sites and sialylation levels that can vary in the …

MTBT1466A is a high-affinity TGFβ3-specific humanized IgG1 monoclonal antibody with
reduced Fc effector function, currently under investigation in clinical trials as a potential anti-…